Esophageal and Gastroesophageal Junction Carcinoma

A 71-year-old male with esophageal carcinoma harboring NTRK1 amplification, based on FoundationOne CDx profiling test, was treated with larotrectinib. Treatment with larotrectinib led to a shrinkage o… (full text at CIViC)

PMID 32323889 · Hempel et al., 2020 · Open in CIViC

Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Upregulation of proteasome subunit beta type 8… (full text at CIViC)

PMID 26894977 · Kwon et al., 2016 · Open in CIViC

In patients with gastric cancer, those with amplification of PIK3CA had shorter overall survival than those without amplification.

PMID 22292935 · Shi et al., 2012 · Open in CIViC

Microarray expression data from 48 patients with gastric adenocarcinoma were analyzed for genes differentially expressed with regard to overall survival. Expression of 294 and 116 genes was enriched i… (full text at CIViC)

PMID 26894977 · Kwon et al., 2016 · Open in CIViC

In 48 patients with advanced gastric cancer, retrospectively analyzed for PTEN expression using IHC, PTEN loss was associated with a shorter duration of response (median 4.2 vs. 6.1 months, p = 0.04) … (full text at CIViC)

PMID 25300346 · Zhang et al., 2015 · Open in CIViC

Tumor samples from 640 patients with metastatic solid tumors were prospectively analyzed with a next-generation sequencing assay to identify molecular targets. 13 (2%) of 640 patients had a RICTOR-aam… (full text at CIViC)

PMID 28028034 · Kim et al., 2017 · Open in CIViC

54 patients with advanced gastric cancer were treated with everolimus. Two patient responsed and potential biomarkers were explored. High pre-treatment expression of phosphorylated RPS6 (pS6; at Ser24… (full text at CIViC)

PMID 22343617 · Yoon et al., 2012 · Open in CIViC

The correlation between FGFR2/SPRY2 and clinicopathologic factors was analyzed by Chi-square to screen the FGFR2/SPRY2-relevant factors. SPRY2 low expression was demonstrated to be significantly assoc… (full text at CIViC)

PMID 28002800 · Xu et al., 2017 · Open in CIViC

In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival.

PMID 19941080 · Yamasaki et al., 2010 · Open in CIViC

In this meta-analysis of 13 studies (564 patients) p53 positivity as defined by high protein expression and/or p53 mutation was associated with improved response to chemotherapy (risk ratio [RR] = 0.7… (full text at CIViC)

PMID 24740294 · Xu et al., 2014 · Open in CIViC

Analysis of 77 esophageal squamous cell carcinoma tumor and normal samples for germline mutations revealed a rare TP53 V197E variant in a single patient. The V197E mutation is in the DNA-binding domai… (full text at CIViC)

PMID 30833958 · Deng et al., 2019 · Open in CIViC

Patients with p53 wild type (as defined by low expression and/or wild-type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 … (full text at CIViC)

PMID 23515910 · Zhang et al., 2013 · Open in CIViC

In 125 gastric tumors, plasma and tissue mRNA levels of TYMS were lower in the raltitrexed sensitive group compared to the resistant group (p = 0.007 and 0.013, respectively).

PMID 22422354 · Shen et al., 2012 · Open in CIViC

Within a preclinical study the inhibitory effects of AZD1775 in esophageal squamous cell carcinoma (ESCC) was demonstrated in both in vitro and in-vivo samples that predominantly displayed high expres… (full text at CIViC)

PMID 31427973 · Bi et al., 2019 · Open in CIViC